|
Ukraine Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Ukraine Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Ukraine .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Ukrainian pharmaceutical and healthcare industry.
Competitive intelligence, Ukrainian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Ukrainian market.
The Ukraine Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Ukraine Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Ukrainian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Ukraine to test other views – a key input for successful budgeting and strategic business planning in the Ukrainian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Ukrainian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Ukraine .
- Exploit The Latest Competitive Ukrainian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Ukraine .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Ukraine Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Ukraine Pharmaceutical And Healthcare Industry SWOT |
| Ukraine Political SWOT |
| Ukraine Economic SWOT |
| Ukraine Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Rating |
| Table: Central And Eastern Europe Pharmaceutical Business Environment Rankings |
| Limits To Potential Returns |
| Risk to Realisation Of Returns |
Chapter - Ukraine – Market Summary |
| Regulatory Regime |
| Intellectual Property Issues |
| Pricing and Reimbursement Issues |
| Other Market Entry Barriers |
Chapter - Industry Developments |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Ukraine's Drug Market Indicators |
| Key Growth Factors – Industry |
| Key Growth Factors – Macroeconomic |
| Growth To Slow Considerably in 2009 |
| Table: Ukraine - Economic Activity |
| OTC Market Forecast |
| Table: OTC Market Indicators (US$mn unless otherwise stated) |
| Prescription Market Forecast |
| Table: Prescription Drug Market Indicators, 2006-2013 (US$mn unless otherwise stated) |
| Generics Market Forecast |
| Table: Generic And Patented Drugs Market Indicators |
| Export/Import Forecasts |
| Table: Import/Export Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Healthcare Data |
Chapter - Competitive Landscape |
| Manufacturing Sector |
| Wholesale |
| Retail |
| Table: Pharmacies And Pharmacy Market Ratios |
Chapter - Company Monitors |
| Arterium |
| Gedeon Richter |
| Krka |
| Lek (Novartis/Sandoz) |
Chapter - Country Snapshot: Ukraine Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Ukraine Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
As Ukraine slips deeper into political confrontation and a deep recession begins to be felt, BMI is forced once again to downgrade its forecasts for the country’s pharmaceutical market. The weakening hyrvnia will translate into a big hit on US dollar market value in 2009. Our updated forecast for 2008 to 2013 sees a US dollar compound annual growth rate (CAGR) of just 1.93% and a local currency rate of 13.09% – a far cry from the 20%-plus US dollar growth rates seen between 2005 and 2007. BMI assumes a sharp but brief recession with the economy returning to a modest 2.3% growth rate in 2010.
Ukraine is in bad shape by any measure and one of the worst affected victims of the global downturn. How quickly it can pull itself out the current tailspin of surging unemployment, bank crisis and political confrontation will determine whether the gains of the last few years – including the development of a modern pharmacy retail network, a small but growing market for innovative medicines and ambitious plans for developing a workable healthcare and medicines insurance system – can be recovered.
The current economic crisis, the devalued currency and the government’s extended and populist campaign against rising pharmaceutical prices is putting huge pressures on manufacturers, distributors and retailers. In January, the head of the Ukrainian Antimonopoly Committee threatened to levy fines equivalent to 10% of company annual earnings for ‘unjustified’ price hikes on medicines. In February, the government pushed ahead on attempts to institute tighter price controls, as well as abolishing the State Service for Medicines and Articles for Medical Use (DSS) – the state certification body – after the Constitutional Court ruled against President Viktor Yushchenko’s previous annulment of the relevant government decrees. The move brings back tough price controls and further muddies the regulatory environment. A new raft of emergency measures looks likely as the economic situation deteriorates.
At the same time, local manufacturers describe an ‘offensive’ being launched against their industry, which they believe is being made a scapegoat for the failure of Prime Minister Yulia Tymoshenko to enact some of the ambitious health-sector reforms it promised when it came into office at the beginning of last year. . The administration of the city of Kyiv showed the dire state of the public healthcare sector when it passed a decree establishing tariffs for medical services – a move immediately challenged by the central government but also one that simply acknowledges that most ostensibly ‘free’ services in fact require under the table payments. The crisis is also filtering through the supply chain to large producers. In February, the head of Gedeon Richter said the company had paid around US$4mn to suppliers in Ukraine and Russia to help them manage the fall in value of the currencies in both countries. Local producers now have an opportunity to regain some market share, but they lack access to credit and investment funds due to the banking crisis.
|
Ukraine Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |